{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:09:08Z","timestamp":1764133748752,"version":"3.41.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ratchadaphiseksomphot fund, Graduate Affairs, Faculty of Medicine, Chulalongkorn University","award":["GA 67\/033","GA 67\/033"],"award-info":[{"award-number":["GA 67\/033","GA 67\/033"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00210-024-03737-w","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T07:42:55Z","timestamp":1735976575000},"page":"7475-7488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic effects of sequential treatment with doxorubicin and zoledronic acid on anticancer effects in estrogen receptor-negative breast cancer cells"],"prefix":"10.1007","volume":"398","author":[{"given":"Apisara","family":"Danpipat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitiya","family":"Rujimongkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patthamapon","family":"Adchariyasakulchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanticha","family":"Wilawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5750","authenticated-orcid":false,"given":"Wannarasmi","family":"Ketchart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"key":"3737_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116142","volume":"171","author":"P Adchariyasakulchai","year":"2024","unstructured":"Adchariyasakulchai P, Sakunrangsit N, Chokyakorn S, Suksanong C, Ketchart W (2024) Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling. Biomed Pharmacother 171:116142. https:\/\/doi.org\/10.1016\/j.biopha.2024.116142","journal-title":"Biomed Pharmacother"},{"key":"3737_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838133","volume":"13","author":"NM Ayoub","year":"2022","unstructured":"Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE (2022) Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Front Pharmacol 13:838133. https:\/\/doi.org\/10.3389\/fphar.2022.838133","journal-title":"Front Pharmacol"},{"issue":"8","key":"3737_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bjoms.2013.05.010","volume":"51","author":"FG Basso","year":"2013","unstructured":"Basso FG, Turrioni AP, Hebling J, de Souza Costa CA (2013) Zoledronic acid decreases gene expression of vascular endothelial growth factor and basic fibroblast growth factor by human epithelial cells. Br J Oral Maxillofac Surg 51(8):971\u2013973. https:\/\/doi.org\/10.1016\/j.bjoms.2013.05.010","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"27","key":"3737_CR4","doi-asserted-by":"publisher","first-page":"10137","DOI":"10.1073\/pnas.0403621101","volume":"101","author":"DK Biswas","year":"2004","unstructured":"Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD (2004) NF-\u03baB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci 101(27):10137\u201310142. https:\/\/doi.org\/10.1073\/pnas.0403621101","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"3737_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2559.2005.02045.x","volume":"46","author":"R Bos","year":"2005","unstructured":"Bos R, Van Diest PJ, De Jong JS, Van Der Groep P, Van Der Valk P, Van Der Wall E (2005) Hypoxia-inducible factor-1\u03b1 is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46(1):31\u201336. https:\/\/doi.org\/10.1111\/j.1365-2559.2005.02045.x","journal-title":"Histopathology"},{"issue":"2","key":"3737_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000093006","volume":"70","author":"DR Budman","year":"2006","unstructured":"Budman DR, Calabro A (2006) Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70(2):147\u2013153. https:\/\/doi.org\/10.1159\/000093006","journal-title":"Oncology"},{"issue":"10","key":"3737_CR7","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, Committee EG (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(10):1674. https:\/\/doi.org\/10.1093\/annonc\/mdz189","journal-title":"Ann Oncol"},{"issue":"1\u20132","key":"3737_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/BD-2010-0307","volume":"32","author":"KJ Chavez","year":"2010","unstructured":"Chavez KJ, Garimella SV, Lipkowitz S (2010) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 32(1\u20132):35\u201348. https:\/\/doi.org\/10.3233\/BD-2010-0307","journal-title":"Breast Dis"},{"issue":"15","key":"3737_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1177\/15353702211011052","volume":"246","author":"YT Cheng","year":"2021","unstructured":"Cheng YT, Liao J, Zhou Q, Huo H, Zellmer L, Tang ZL, Ma H, Hong W, Liao DJ (2021) Zoledronic acid modulates osteoclast apoptosis through activation of the NF-kappaB signaling pathway in ovariectomized rats. Exp Biol Med (Maywood) 246(15):1727\u20131739. https:\/\/doi.org\/10.1177\/15353702211011052","journal-title":"Exp Biol Med (Maywood)"},{"key":"3737_CR10","doi-asserted-by":"publisher","unstructured":"Devanaboyina M, Kaur J, Whiteley E, Lin L, Einloth K, Morand S, Stanbery L, Hamouda D, Nemunaitis J (2022) NF-\u03baB signaling in tumor pathways focusing on breast and ovarian cancer [review]. Oncol Rev 16. https:\/\/doi.org\/10.3389\/or.2022.10568","DOI":"10.3389\/or.2022.10568"},{"issue":"17","key":"3737_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40265-016-0662-4","volume":"76","author":"S Dhillon","year":"2016","unstructured":"Dhillon S (2016) Zoledronic acid (reclast((R)), aclasta((R))): a review in osteoporosis. Drugs 76(17):1683\u20131697. https:\/\/doi.org\/10.1007\/s40265-016-0662-4","journal-title":"Drugs"},{"issue":"3","key":"3737_CR12","doi-asserted-by":"publisher","first-page":"E734","DOI":"10.9778\/cmajo.20170030","volume":"5","author":"S Fallahpour","year":"2017","unstructured":"Fallahpour S, Navaneelan T, De P, Borgo A (2017) Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 5(3):E734\u2013E739. https:\/\/doi.org\/10.9778\/cmajo.20170030","journal-title":"CMAJ Open"},{"issue":"1","key":"3737_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/sj.bjc.6601009","volume":"89","author":"O Fromigue","year":"2003","unstructured":"Fromigue O, Kheddoumi N, Body JJ (2003) Bisphosphonates antagonise bone growth factors\u2019 effects on human breast cancer cells survival. Br J Cancer 89(1):178\u2013184. https:\/\/doi.org\/10.1038\/sj.bjc.6601009","journal-title":"Br J Cancer"},{"issue":"2","key":"3737_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176\u2013198. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177","journal-title":"Cancer Discov"},{"issue":"5","key":"3737_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1172\/JCI22087","volume":"114","author":"E Giraudo","year":"2004","unstructured":"Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5):623\u2013633. https:\/\/doi.org\/10.1172\/JCI22087","journal-title":"J Clin Invest"},{"key":"3737_CR16","doi-asserted-by":"publisher","first-page":"28217","DOI":"10.1038\/srep28217","volume":"6","author":"Y Gu","year":"2016","unstructured":"Gu Y, Helenius M, Vaananen K, Bulanova D, Saarela J, Sokolenko A, Martens J, Imyanitov E, Kuznetsov S (2016) BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. Sci Rep 6:28217. https:\/\/doi.org\/10.1038\/srep28217","journal-title":"Sci Rep"},{"key":"3737_CR17","doi-asserted-by":"publisher","unstructured":"Hao YU, Y. Z., Ying Zhang, Dong HUA. (2012). The biological effects of zoledronic acid in combination with doxorubicin on SGC-7901 cell line of gastric cancer. Chin J Geriatr 8;711-715. https:\/\/doi.org\/10.3760\/cma.j.issn.0254-9026.2012.08.023","DOI":"10.3760\/cma.j.issn.0254-9026.2012.08.023"},{"issue":"2","key":"3737_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3892\/ijmm.2019.4207","volume":"44","author":"XL Huang","year":"2019","unstructured":"Huang XL, Huang LY, Cheng YT, Li F, Zhou Q, Wu C, Shi QH, Guan ZZ, Liao J, Hong W (2019) Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-\u03baB and JNK signalling pathways. Int J Mol Med 44(2):582\u2013592. https:\/\/doi.org\/10.3892\/ijmm.2019.4207","journal-title":"Int J Mol Med"},{"issue":"1","key":"3737_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1475-2867-12-48","volume":"12","author":"T Ibrahim","year":"2012","unstructured":"Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D (2012) Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int 12(1):48. https:\/\/doi.org\/10.1186\/1475-2867-12-48","journal-title":"Cancer Cell Int"},{"issue":"3","key":"3737_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3892\/ijo.2016.3613","volume":"49","author":"T Ibrahim","year":"2016","unstructured":"Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D (2016) [Corrigendum] Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. Int J Oncol 49(3):1260. https:\/\/doi.org\/10.3892\/ijo.2016.3613","journal-title":"Int J Oncol"},{"issue":"8","key":"3737_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84(8):1126\u20131134. https:\/\/doi.org\/10.1054\/bjoc.2001.1727","journal-title":"Br J Cancer"},{"issue":"9","key":"3737_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.humpath.2015.05.010","volume":"46","author":"MH Jang","year":"2015","unstructured":"Jang MH, Kim HJ, Kim EJ, Chung YR, Park SY (2015) Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol 46(9):1267\u20131274. https:\/\/doi.org\/10.1016\/j.humpath.2015.05.010","journal-title":"Hum Pathol"},{"issue":"1","key":"3737_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12885-021-07860-2","volume":"21","author":"H Jiang","year":"2021","unstructured":"Jiang H, Li H (2021) Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer 21(1):149. https:\/\/doi.org\/10.1186\/s12885-021-07860-2","journal-title":"BMC Cancer"},{"key":"3737_CR24","unstructured":"Kars MD, Iseri OD, Ural AU, Gunduz U (2007) In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 27(6B):4031\u20134037. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18225567"},{"issue":"6","key":"3737_CR25","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1182\/blood-2003-01-0305","volume":"102","author":"J Kuroda","year":"2003","unstructured":"Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG, Maekawa T (2003) The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102(6):2229\u20132235. https:\/\/doi.org\/10.1182\/blood-2003-01-0305","journal-title":"Blood"},{"issue":"2","key":"3737_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12032-011-9904-1","volume":"29","author":"X-Y Li","year":"2012","unstructured":"Li X-Y, Lin Y-C, Huang W-L, Hong C-Q, Chen J-Y, You Y-J, Li W-B (2012) Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med Oncol 29(2):714\u2013720. https:\/\/doi.org\/10.1007\/s12032-011-9904-1","journal-title":"Med Oncol"},{"issue":"1","key":"3737_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"3737_CR28","doi-asserted-by":"publisher","unstructured":"Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES (2014) Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget 5(9);2736\u20132749. https:\/\/doi.org\/10.18632\/oncotarget.1932","DOI":"10.18632\/oncotarget.1932"},{"issue":"1","key":"3737_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tby003","volume":"1","author":"N Mohan","year":"2018","unstructured":"Mohan N, Jiang J, Dokmanovic M, Wu WJ (2018) Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther 1(1):13\u201317. https:\/\/doi.org\/10.1093\/abt\/tby003","journal-title":"Antib Ther"},{"issue":"3","key":"3737_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ijc.20602","volume":"113","author":"HL Neville-Webbe","year":"2005","unstructured":"Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113(3):364\u2013371. https:\/\/doi.org\/10.1002\/ijc.20602","journal-title":"Int J Cancer"},{"key":"3737_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1471-2407-14-169","volume":"14","author":"G Odri","year":"2014","unstructured":"Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Redini F (2014) Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing\u2019s sarcoma via inhibition of cell migration. BMC Cancer 14:169. https:\/\/doi.org\/10.1186\/1471-2407-14-169","journal-title":"BMC Cancer"},{"issue":"1","key":"3737_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s43046-021-00072-6","volume":"33","author":"AS Oguntade","year":"2021","unstructured":"Oguntade AS, Al-Amodi F, Alrumayh A, Alobaida M, Bwalya M (2021) Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Canc Inst 33(1):15. https:\/\/doi.org\/10.1186\/s43046-021-00072-6","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"3737_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/ar2575","volume":"11","author":"KM Oliver","year":"2009","unstructured":"Oliver KM, Taylor CT, Cummins EP (2009) Hypoxia. Regulation of NFkappaB signalling during inflammation: the role of hydroxylases. Arthritis Res Ther 11(1):215. https:\/\/doi.org\/10.1186\/ar2575","journal-title":"Arthritis Res Ther"},{"issue":"16","key":"3737_CR34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jnci\/djn240","volume":"100","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100(16):1167\u20131178. https:\/\/doi.org\/10.1093\/jnci\/djn240","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"3737_CR35","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1158\/1535-7163.MCT-09-0462","volume":"8","author":"PD Ottewell","year":"2009","unstructured":"Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 8(10):2821\u20132832. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0462","journal-title":"Mol Cancer Ther"},{"key":"3737_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114822","volume":"163","author":"E Pavitra","year":"2023","unstructured":"Pavitra E, Kancharla J, Gupta VK, Prasad K, Sung JY, Kim J, Tej MB, Choi R, Lee JH, Han YK, Raju GSR, Bhaskar L, Huh YS (2023) The role of NF-kappaB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. Biomed Pharmacother 163:114822. https:\/\/doi.org\/10.1016\/j.biopha.2023.114822","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3737_CR37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/aps.2015.42","volume":"36","author":"H Qiao","year":"2015","unstructured":"Qiao H, Wang TY, Yan W, Qin A, Fan QM, Han XG, Wang YG, Tang TT (2015) Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro. Acta Pharmacol Sin 36(9):1085\u20131098. https:\/\/doi.org\/10.1038\/aps.2015.42","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"3737_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cells5020016","volume":"5","author":"AL Rinkenbaugh","year":"2016","unstructured":"Rinkenbaugh AL, Baldwin AS (2016) The NF-\u03baB pathway and cancer stem cells. Cells 5(2):16. https:\/\/doi.org\/10.3390\/cells5020016","journal-title":"Cells"},{"issue":"11","key":"3737_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078641","volume":"8","author":"TJ Robinson","year":"2013","unstructured":"Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, Zacksenhaus E (2013) RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE 8(11):e78641. https:\/\/doi.org\/10.1371\/journal.pone.0078641","journal-title":"PLoS ONE"},{"key":"3737_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/BCTT.S46020","volume":"6","author":"DM Roy","year":"2014","unstructured":"Roy DM, Walsh LA (2014) Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors. Breast Cancer (Dove Med Press) 6:81\u201391. https:\/\/doi.org\/10.2147\/BCTT.S46020","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"3737_CR41","doi-asserted-by":"publisher","unstructured":"Santolla MF, Talia M, Maggiolini M (2021) S100A4 is involved in stimulatory effects elicited by the FGF2\/FGFR1 signaling pathway in triple-negative breast cancer (TNBC) cells. Int J Mol Sci 22(9). https:\/\/doi.org\/10.3390\/ijms22094720","DOI":"10.3390\/ijms22094720"},{"issue":"7","key":"3737_CR42","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1535-7163.MCT-12-0304","volume":"12","author":"AJ Schech","year":"2013","unstructured":"Schech AJ, Kazi AA, Gilani RA, Brodie AH (2013) Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-kappaB. Mol Cancer Ther 12(7):1356\u20131366. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0304","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"3737_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21(7):440\u2013446. https:\/\/doi.org\/10.1097\/FPC.0b013e32833ffb56","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"3737_CR44","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/bcr1543","volume":"8","author":"AU Ural","year":"2006","unstructured":"Ural AU, Avcu F, Candir M, Guden M, Ozcan MA (2006) In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8(4):R52. https:\/\/doi.org\/10.1186\/bcr1543","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3737_CR45","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1186\/s12885-020-07568-9","volume":"20","author":"L Wang","year":"2020","unstructured":"Wang L, Fang D, Xu J, Luo R (2020) Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer 20(1):1059. https:\/\/doi.org\/10.1186\/s12885-020-07568-9","journal-title":"BMC Cancer"},{"issue":"3","key":"3737_CR46","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","volume":"302","author":"J Wood","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302(3):1055\u20131061. https:\/\/doi.org\/10.1124\/jpet.102.035295","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"3737_CR47","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/01.cad.0000175582.01446.6f","volume":"16","author":"JK Woodward","year":"2005","unstructured":"Woodward JK, Neville-Webbe HL, Coleman RE, Holen I (2005) Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 16(8):845\u2013854. https:\/\/doi.org\/10.1097\/01.cad.0000175582.01446.6f","journal-title":"Anticancer Drugs"},{"issue":"1","key":"3737_CR48","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1515\/med-2022-0463","volume":"17","author":"J Xiao","year":"2022","unstructured":"Xiao J, Li Y, Cheng G, Xu G (2022) Zoledronate promotes ECM degradation and apoptosis via Wnt\/beta-catenin. Open Med (Wars) 17(1):768\u2013780. https:\/\/doi.org\/10.1515\/med-2022-0463","journal-title":"Open Med (Wars)"},{"issue":"1","key":"3737_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3737_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","volume":"3","author":"J Zekri","year":"2014","unstructured":"Zekri J, Mansour M, Karim SM (2014) The anti-tumour effects of zoledronic acid. J Bone Oncol 3(1):25\u201335. https:\/\/doi.org\/10.1016\/j.jbo.2013.12.001","journal-title":"J Bone Oncol"},{"issue":"1","key":"3737_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1349-7006.2011.02113.x","volume":"103","author":"M Zhao","year":"2012","unstructured":"Zhao M, Tominaga Y, Ohuchida K, Mizumoto K, Cui L, Kozono S, Fujita H, Maeyama R, Toma H, Tanaka M (2012) Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Sci 103(1):58\u201366. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02113.x","journal-title":"Cancer Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03737-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T10:51:49Z","timestamp":1748602309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03737-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3737"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03737-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments using human cell lines were exempted by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB Number: 0180\/66, COE No.017\/2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}